IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 903 
Expressing support for the designation of November as ‘‘Complex Regional 
Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness 
Month’’. 
IN THE HOUSE OF REPRESENTATIVES 
NOVEMBER 20, 2025 
Mr. TONKO (for himself and Mrs. MILLER-MEEKS) submitted the following 
resolution; which was referred to the Committee on Energy and Commerce 
RESOLUTION 
Expressing support for the designation of November as 
‘‘Complex Regional Pain Syndrome and Reflex Sympa-
thetic Dystrophy Syndrome Awareness Month’’. 
Whereas Complex Regional Pain Syndrome, also known as 
Reflex Sympathetic Dystrophy Syndrome, is a rare, 
neuro-inflammatory syndrome characterized by intense 
chronic pain, swelling, vascular changes, and functional 
impairment of the limbs that may result from simple 
trauma, injury, infection, or surgery that can lead to dis-
ability; 
Whereas Complex Regional Pain Syndrome can become de-
bilitating unless diagnosed early and treated appro-
priately; 
VerDate Sep 11 2014 
00:58 Nov 22, 2025
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR903.IH
HR903
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 903 IH 
Whereas although Complex Regional Pain Syndrome was 
first identified during the American Civil War, it remains 
an obscure and poorly understood condition for which 
there is no single test for diagnosis, and there is no cure; 
Whereas Complex Regional Pain Syndrome is more common 
in women than men with a ratio of 3.5:1, with peak inci-
dence in middle-aged and older adults, especially post 
menopausal women; 
Whereas the incidence of Complex Regional Pain Syndrome 
is low worldwide, with regional rates generally between 5 
and 29 per 100,000 individuals, higher in women and 
older adults, and even lower in children; 
Whereas individuals with Complex Regional Pain Syndrome, 
like many other rare disorders, experience challenges with 
obtaining a diagnosis, limited treatment options, and dif-
ficulty finding and accessing treatment centers and physi-
cians with expertise in Complex Regional Pain Syndrome; 
Whereas because the disorder affects multiple systems of the 
body, a patient with Complex Regional Pain Syndrome 
often requires access to care from experts across a range 
of medical specialties; 
Whereas, to date, there is no treatment for Complex Regional 
Pain Syndrome that is approved by the Food and Drug 
Administration (in this resolution referred to as the 
‘‘FDA’’); 
Whereas there is a critical need for research and development 
to advance treatments for Complex Regional Pain Syn-
drome; 
Whereas, as a result of the Orphan Drug Act, there have 
been important advances in research on and treatment 
VerDate Sep 11 2014 
00:58 Nov 22, 2025
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR903.IH
HR903
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 903 IH 
for rare diseases, including development efforts in Com-
plex Regional Pain Syndrome; 
Whereas the FDA established the Accelerated Approval Path-
way in 1992 and Congress codified the pathway in 2012; 
Whereas the Accelerated Approval Pathway is an important 
pathway for rare and ultrarare diseases as it allows for 
‘‘earlier approval of drugs that treat serious conditions, 
and fill an unmet medical need’’; 
Whereas Congress and the FDA have affirmed the impor-
tance of incorporating the patient perspective throughout 
the drug review process through the FDA’s Patient-Fo-
cused Drug Development program; 
Whereas the Reflex Sympathetic Dystrophy Syndrome Asso-
ciation, a nonprofit organization founded in 1984 to pro-
vide support, education, and hope to all affected by the 
pain and disability of CRPS/RSD, while driving research 
to develop better treatments and a cure for Complex Re-
gional Pain Syndrome; and 
Whereas ‘‘Complex Regional Pain Syndrome and Reflex Sym-
pathetic Dystrophy Syndrome Awareness Month’’ is ex-
pected to be observed in the United States for years to 
come, providing hope and information for patients, care-
givers, and families around the country: Now, therefore, 
be it 
Resolved, That the House of Representatives— 
(1) expresses support for the designation of 
‘‘Complex Regional Pain Syndrome and Reflex Sym-
pathetic Dystrophy Syndrome Awareness Month’’; 
and 
VerDate Sep 11 2014 
00:58 Nov 22, 2025
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR903.IH
HR903
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 903 IH 
(2) recognizes the importance of, with respect 
to Complex Regional Pain Syndrome and Reflex 
Sympathetic 
Dystrophy 
Syndrome 
Awareness 
Month— 
(A) improving awareness; 
(B) encouraging accurate and early diag-
nosis; 
(C) advancing research; 
(D) 
developing 
new 
treatments, 
diagnostics, and cures; and 
(E) identifying regulatory pathways for 
drug development of ultrarare diseases like 
Complex Regional Pain Syndrome and Reflex 
Sympathetic Dystrophy Syndrome. 
Æ 
VerDate Sep 11 2014 
00:58 Nov 22, 2025
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR903.IH
HR903
ssavage on LAPJG3WLY3PROD with BILLS